Alex Quok An Teo1, Keng Lin Wong2,3,4, Liang Shen5, Jia Ying Lim4, Wei Seong Toh3,6, Eng Hin Lee1,3,4, James Hoi Po Hui1,3,4. 1. University Orthopaedics, Hand and Reconstructive Microsurgery Cluster, National University Health System, Singapore. 2. Department of Orthopaedic Surgery, Sengkang General Hospital, Sengkang Health, Singhealth, Singapore. 3. NUS Tissue Engineering Programme, Life Sciences Institute, National University of Singapore, Singapore. 4. Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 5. Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 6. Faculty of Dentistry, National University of Singapore, Singapore.
Abstract
BACKGROUND: The use of bone marrow-derived mesenchymal stem cells (BMSCs) in cartilage repair procedures circumvents some of the limitations of autologous chondrocyte implantation (ACI), but long-term outcomes for this newer procedure are lacking. The authors previously reported comparable outcomes for the 2 procedures at 2-year follow-up. PURPOSE/HYPOTHESIS: The purpose was to compare the long-term clinical outcomes of ACI versus BMSCs. It was hypothesized that there would be no significant difference between the groups in terms of patient-reported outcome scores and safety outcomes at 10-year follow-up. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: Seventy-two patients who underwent either ACI or BMSC implantation-matched in terms of age and lesion site- were followed up to a median of at least 10 years. Patients were assessed with the 36-item Short Form Health Survey (SF-36), the International Knee Documentation Committee knee evaluation form, the Lysholm Knee Score, and the Tegner Activity Scale. In addition, information was obtained regarding any additional surgical procedures as well as safety data, with particular attention to infection and tumor formation. RESULTS: There was an improvement in all patient-reported outcomes scores apart from the Mental Component Summary of the SF-36 after cartilage repair surgery. There was no significant difference in any of the patient-reported outcomes between cohorts at any time point. Six and 5 patients in the ACI and BMSC groups, respectively, underwent subsequent surgical procedures, including 1 total knee replacement in the BMSC group. None of the patients in either group developed any deep infection or tumor within the follow-up period. CONCLUSION: BMSC implantation used for the treatment of chondral defects of the knee appears to result in equivalent clinical outcomes to first-generation ACI at up to 10 years, with no apparent increased tumor formation risk.
BACKGROUND: The use of bone marrow-derived mesenchymal stem cells (BMSCs) in cartilage repair procedures circumvents some of the limitations of autologous chondrocyte implantation (ACI), but long-term outcomes for this newer procedure are lacking. The authors previously reported comparable outcomes for the 2 procedures at 2-year follow-up. PURPOSE/HYPOTHESIS: The purpose was to compare the long-term clinical outcomes of ACI versus BMSCs. It was hypothesized that there would be no significant difference between the groups in terms of patient-reported outcome scores and safety outcomes at 10-year follow-up. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: Seventy-two patients who underwent either ACI or BMSC implantation-matched in terms of age and lesion site- were followed up to a median of at least 10 years. Patients were assessed with the 36-item Short Form Health Survey (SF-36), the International Knee Documentation Committee knee evaluation form, the Lysholm Knee Score, and the Tegner Activity Scale. In addition, information was obtained regarding any additional surgical procedures as well as safety data, with particular attention to infection and tumor formation. RESULTS: There was an improvement in all patient-reported outcomes scores apart from the Mental Component Summary of the SF-36 after cartilage repair surgery. There was no significant difference in any of the patient-reported outcomes between cohorts at any time point. Six and 5 patients in the ACI and BMSC groups, respectively, underwent subsequent surgical procedures, including 1 total knee replacement in the BMSC group. None of the patients in either group developed any deep infection or tumor within the follow-up period. CONCLUSION: BMSC implantation used for the treatment of chondral defects of the knee appears to result in equivalent clinical outcomes to first-generation ACI at up to 10 years, with no apparent increased tumor formation risk.
Authors: Pavel Neckar; Hana Potockova; Jaroslav Branis; Vojtech Havlas; Tomas Novotny; Dominika Lykova; Jana Gujski; Ivana Drahoradova; Katerina Ruzickova; Jana Kaclova; Petr Skala; Peter O Bauer Journal: Int Orthop Date: 2022-07-19 Impact factor: 3.479
Authors: Dong Hwan Lee; Chae-Gwan Kong; Yong-Woon Shin; Saif Ahmed; Asode Ananthram Shetty; Myung Sang Moon; Seok Jung Kim Journal: Ann Transl Med Date: 2020-07
Authors: M Adelaide Asnaghi; Laura Power; Andrea Barbero; Martin Haug; Ruth Köppl; David Wendt; Ivan Martin Journal: Front Bioeng Biotechnol Date: 2020-04-07
Authors: Kris T C Hede; Bjørn B Christensen; Morten L Olesen; Jesper Skovhus Thomsen; Casper B Foldager; Wei Seong Toh; Sai Kiang Lim; Martin C Lind Journal: Cartilage Date: 2021-07-26 Impact factor: 3.117
Authors: Rhayra B Dias; João A M Guimarães; Marco B Cury; Leonardo R Rocha; Elaine S da Costa; Liebert P Nogueira; Camila Hochman-Mendez; Anneliese Fortuna-Costa; Anna Karoline F Silva; Karin S Cunha; Sergio A L de Souza; Maria Eugênia L Duarte; Rafaela C Sartore; Danielle C Bonfim Journal: Stem Cells Int Date: 2019-11-07 Impact factor: 5.443